pitavastatin magnesium - Profile

What are the generic drug sources for pitavastatin magnesium and what is the scope of freedom to operate?

Pitavastatin magnesium is the generic ingredient in one branded drug marketed by Medicure and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Pitavastatin magnesium has two patent family members in two countries.

Summary for pitavastatin magnesium

International Patents:	2
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for pitavastatin magnesium

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for pitavastatin magnesium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-001	Jul 14, 2017		DISCN	Yes	No			Y	Y
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-002	Jul 14, 2017		RX	Yes	No			Y	Y
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-003	Jul 14, 2017		RX	Yes	Yes			Y	Y

International Patents for pitavastatin magnesium

Country	Patent Number	Title	Estimated Expiration
Japan	2013516459
World Intellectual Property Organization (WIPO)	2011089623

Pitavastatin Magnesium: Investment Landscape and Fundamental Analysis

Last updated: February 19, 2026

Pitavastatin magnesium is a statin drug used to lower cholesterol levels. Its market presence is primarily driven by demand for cardiovascular disease prevention and management. Key investment considerations include its patent status, competitive landscape, and market penetration in major pharmaceutical regions. The drug's efficacy in reducing low-density lipoprotein cholesterol (LDL-C) and its safety profile are fundamental to its commercial viability.

What is Pitavastatin Magnesium's Patent Status?

The intellectual property landscape for pitavastatin magnesium is critical for understanding its market exclusivity and potential for generic competition. The original patents protecting the composition of matter and method of use for pitavastatin have largely expired in major markets, opening the door for generic manufacturers.

• Original Composition of Matter Patents: These patents, which protected the chemical structure of pitavastatin, have expired in the United States and Europe. For example, the primary US patent for pitavastatin (US4,994,459) expired in 2009.
• Formulation Patents: Patents related to specific formulations, such as pitavastatin magnesium, may have had later expiration dates. However, information on the specific expiry dates of all formulation patents is not publicly consolidated. Generic companies have actively pursued legal challenges to invalidate or circumvent these remaining patent protections.
• Market Exclusivity Periods: Beyond patent expiry, regulatory bodies in different regions grant market exclusivity periods. For instance, in the US, the Hatch-Waxman Act provides for 5 years of data exclusivity for new chemical entities. Pitavastatin was approved in Japan in 2003 and in the US as Livalo in 2009, indicating that the initial exclusivity windows have closed in these regions.
• Generic Approvals: The expiration of key patents has led to the approval and market entry of generic pitavastatin products. For example, generic versions of pitavastatin have been approved by the U.S. Food and Drug Administration (FDA). This indicates the end of brand-name market exclusivity and the commencement of price-based competition.

What is the Competitive Landscape for Pitavastatin Magnesium?

The market for cholesterol-lowering drugs is highly competitive, with pitavastatin magnesium facing pressure from both branded and generic statins, as well as newer classes of lipid-lowering agents.

Key Competitors:

• Other Statins:
  • Atorvastatin (Lipitor): One of the most widely prescribed statins globally. Generic availability has significantly reduced its price.
  • Simvastatin (Zocor): Another established statin with broad market penetration and generic availability.
  • Rosuvastatin (Crestor): Known for its high potency in lowering LDL-C. Generic versions are now available, intensifying competition.
  • Pravastatin (Pravachol): An older statin with a long history of use.
  • Lovastatin (Mevacor): One of the first statins introduced to the market.
• Non-Statin Lipid-Lowering Agents:
  • Ezetimibe (Zetia): Inhibits cholesterol absorption in the intestine. Often used in combination with statins.
  • PCSK9 Inhibitors (e.g., Evolocumab - Repatha, Alirocumab - Praluent): Monoclonal antibodies that significantly reduce LDL-C levels. These are typically reserved for high-risk patients or those intolerant to statins due to their higher cost.
  • Bile Acid Sequestrants: Older drugs that bind to bile acids in the gut, promoting cholesterol excretion.
  • Fibrates: Primarily used to lower triglycerides and raise HDL-C.

Market Dynamics:

• Genericization: The primary driver of competition for pitavastatin magnesium is the availability of generic alternatives. Once a branded drug goes off-patent, multiple generic manufacturers can enter the market, leading to significant price erosion. This has been observed with pitavastatin.
• Pricing: Price is a major factor in the statin market. Generic statins are considerably cheaper than their branded counterparts, influencing prescribing patterns and formulary placement by insurance providers.
• Efficacy and Safety Profiles: While all statins aim to lower LDL-C, they differ in their potency and potential side effects. Pitavastatin magnesium is generally considered to have a favorable efficacy and safety profile, comparable to other potent statins. However, established statins with extensive clinical trial data and long-term real-world evidence may have an advantage in physician confidence.
• Combination Therapies: The development of fixed-dose combination drugs, such as pitavastatin/ezetimibe, offers potential to improve patient adherence and provide enhanced lipid-lowering. This strategy can create new market opportunities and extend product life cycles.
• Geographic Variations: Market penetration and competitive intensity vary by region. In the United States and Europe, generic competition is already robust. In emerging markets, branded drugs may retain market share longer due to pricing and access issues.

What are the Market Opportunities for Pitavastatin Magnesium?

Despite the competitive pressures, specific market opportunities exist for pitavastatin magnesium, particularly in regions where its market penetration is less saturated or where its unique attributes are leveraged.

• Emerging Markets: As healthcare access and income levels rise in countries across Asia, Latin America, and Africa, the demand for effective and affordable cardiovascular medications like statins is increasing. Pitavastatin magnesium, especially in its generic form, can capture market share in these regions.
• Combination Therapies: The development and marketing of fixed-dose combinations involving pitavastatin magnesium present a significant opportunity. A combination product with ezetimibe, for example, can offer enhanced efficacy and improved patient adherence, differentiating it from single-agent statins. The market for combination lipid-lowering therapies is growing.
• Specific Patient Populations: While statins are broadly prescribed, there may be niche opportunities. For instance, if pitavastatin magnesium demonstrates a particular advantage in specific patient sub-groups (e.g., those with certain genetic predispositions to statin-induced myopathy, or those requiring aggressive LDL-C lowering), targeted marketing could be effective. However, robust clinical data supporting such advantages is required.
• Generic Market Consolidation: For generic manufacturers, opportunities lie in efficient production, robust supply chains, and strategic partnerships to gain market access. Companies that can offer competitive pricing and reliable supply of high-quality generic pitavastatin magnesium are well-positioned.
• Potential for New Indications: While the primary indication is hyperlipidemia, any future research demonstrating efficacy in other cardiovascular-related areas could open new avenues. This is a longer-term, speculative opportunity.

What are the Risks Associated with Investing in Pitavastatin Magnesium?

Investing in pharmaceuticals, particularly in the generic space, carries inherent risks. For pitavastatin magnesium, these risks are primarily tied to market dynamics, regulatory hurdles, and the ongoing evolution of cardiovascular treatment.

• Intense Generic Competition and Price Erosion: The most significant risk is the rapid and aggressive price competition that follows patent expiry. Multiple generic manufacturers vying for market share can lead to substantial price reductions, impacting profitability for all players, including manufacturers of the branded product and generic producers.
• Evolving Treatment Guidelines: Cardiovascular treatment guidelines are periodically updated based on new clinical research. Shifts in these guidelines, potentially favoring newer drug classes or different statin recommendations, could reduce the overall demand for pitavastatin magnesium. For example, if PCSK9 inhibitors become more cost-effective or are recommended for broader use, statin use might be re-evaluated.
• Statin Intolerance and Side Effects: Despite generally favorable safety profiles, statins are associated with side effects, most notably muscle-related issues (myopathy) and, rarely, liver enzyme elevations. Patient intolerance or concerns about side effects can lead to discontinuation or avoidance of statins, impacting market size.
• Development of Superior Therapies: Ongoing research into novel lipid-lowering agents, including non-statin therapies with potentially greater efficacy or improved safety profiles, poses a long-term threat. The emergence of a significantly superior treatment option could displace pitavastatin magnesium.
• Regulatory Scrutiny and Compliance: Pharmaceutical companies face rigorous regulatory oversight. Any issues related to manufacturing quality, adverse event reporting, or marketing practices can lead to sanctions, product recalls, or reputational damage, all of which negatively impact investment value.
• Supply Chain Disruptions: The global pharmaceutical supply chain is complex. Disruptions due to geopolitical events, raw material shortages, or manufacturing issues can impact the availability and cost of production for pitavastatin magnesium.
• Reimbursement Pressures: Payer organizations (insurance companies, government health programs) exert significant pressure on drug pricing and formulary placement. Less favorable reimbursement policies can limit patient access and sales volume.

What are the Key Financial and Market Metrics for Pitavastatin Magnesium?

Analyzing the financial and market metrics of pitavastatin magnesium provides quantitative insights into its performance and investment potential. These metrics are crucial for evaluating the commercial success of the drug and its associated companies.

• Sales Revenue: For branded pitavastatin (e.g., Livalo), sales revenue figures indicate market adoption and pricing power. Post-genericization, revenue trends will reflect the impact of competition and volume increases. For example, Livalo achieved significant sales in its peak years. Data from companies like Kowa and its licensees would provide specific revenue figures.
• Market Share: Pitavastatin magnesium's market share within the broader hyperlipidemia market, and specifically within the statin segment, is a key indicator. This is often tracked by market research firms such as IQVIA, GlobalData, and EvaluatePharma. Its share is likely to be lower than blockbuster statins like atorvastatin or rosuvastatin.
• Prescription Volume: Tracking the number of prescriptions (Rx) for pitavastatin magnesium provides insight into patient utilization and physician prescribing habits. This metric is essential for assessing the underlying demand for the drug.
• Pricing Trends: Monitoring average selling prices (ASPs) for both the branded and generic versions of pitavastatin magnesium is critical. Significant price declines after generic entry are expected and are a primary factor in assessing profitability.
• Generic Entry Timeline and Impact: The date of generic entry into key markets (US, EU5, Japan) and the subsequent percentage of price erosion are vital metrics. For instance, a 50-80% price drop within 12-24 months of generic launch is typical for statins.
• Cost of Goods Sold (COGS): For generic manufacturers, COGS is a crucial determinant of profitability. Efficient manufacturing processes and access to cost-effective raw materials are key.
• Research and Development (R&D) Investment: For companies developing new formulations or combination therapies involving pitavastatin, R&D expenditure data is relevant. This indicates investment in future growth.
• Partnership and Licensing Agreements: The financial terms of licensing agreements and partnerships for pitavastatin magnesium (e.g., royalties, milestone payments) are important for evaluating revenue streams for the originator and costs for licensees.
• Gross Profit Margins: Comparing gross profit margins for branded versus generic pitavastatin products highlights the impact of market dynamics on profitability. Generic margins are typically lower but rely on higher volumes.

What are the Regulatory Considerations for Pitavastatin Magnesium?

The regulatory landscape for pitavastatin magnesium is multifaceted, encompassing approvals for marketing, post-market surveillance, and generic drug pathways. Compliance with these regulations is essential for market access and continued commercialization.

• Marketing Authorizations: Pitavastatin magnesium requires approval from regulatory agencies in each target country before it can be marketed. This includes the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. The approval process involves rigorous review of preclinical and clinical data demonstrating safety and efficacy.
• Generic Drug Approval Pathway: For generic versions, manufacturers must demonstrate bioequivalence to the reference listed drug (RLD), which is typically the branded product. In the U.S., this is achieved through an Abbreviated New Drug Application (ANDA). The ANDA process is generally less costly and time-consuming than the New Drug Application (NDA) for novel compounds.
• Patent Litigation and Exclusivity: Regulatory bodies, such as the FDA, manage the Hatch-Waxman Act provisions, which govern patent challenges and the subsequent granting of market exclusivity for generic drugs. Understanding patent expiry dates and any ongoing litigation is crucial.
• Post-Market Surveillance (Pharmacovigilance): Once a drug is approved, ongoing monitoring for adverse events is mandatory. Companies must report any new safety concerns to regulatory authorities. Changes in safety profiles can lead to label updates, restrictions, or even market withdrawal.
• Manufacturing Standards (GMP): Pharmaceutical manufacturing must adhere to strict Good Manufacturing Practice (GMP) guidelines. Regulatory agencies conduct inspections to ensure compliance. Any deviations can result in significant penalties, product recalls, or import alerts.
• Labeling and Advertising: Regulatory agencies review and approve drug labeling, including prescribing information, indications, contraindications, warnings, and adverse reactions. Marketing materials must also comply with regulations to prevent misleading claims.
• Drug Master Files (DMFs): For active pharmaceutical ingredients (APIs), manufacturers often submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, quality control, and facilities. Generic drug applications will reference these DMFs.
• International Harmonization: Efforts towards international harmonization of regulatory requirements, such as those by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), aim to streamline global drug development and approval processes.

Key Takeaways

Pitavastatin magnesium operates in a highly competitive lipid-lowering drug market. Its primary investment consideration is the impact of genericization following patent expiries, which has led to significant price erosion. While direct competition from other statins and emerging non-statin therapies is intense, opportunities exist in emerging markets and through the development of combination therapies. Key risks include aggressive price competition, evolving treatment guidelines, and the potential for superior future therapies. Financial analysis should focus on sales revenue trends, market share, pricing dynamics, and generic entry impacts. Regulatory considerations are paramount, covering approval processes, GMP compliance, and post-market surveillance.

Frequently Asked Questions

1. What is the primary mechanism of action for pitavastatin magnesium? Pitavastatin magnesium is a statin that inhibits HMG-CoA reductase, a key enzyme in the liver responsible for cholesterol synthesis. This leads to a reduction in intracellular cholesterol, which in turn upregulates LDL receptors on hepatocytes, increasing the clearance of LDL-C from the bloodstream.

2. How does pitavastatin magnesium compare in efficacy to other widely used statins? Pitavastatin magnesium has demonstrated efficacy comparable to other potent statins like atorvastatin and rosuvastatin in lowering LDL-C. Clinical studies have shown it can achieve significant reductions in LDL-C and also modestly affect other lipid parameters like HDL-C and triglycerides.

3. What are the main side effects associated with pitavastatin magnesium? Common side effects of pitavastatin magnesium are similar to other statins and include muscle pain (myalgia), headache, and gastrointestinal disturbances. More serious, though rare, side effects can include rhabdomyolysis (severe muscle breakdown) and elevated liver enzymes.

4. Are there any significant unmet needs that pitavastatin magnesium is uniquely positioned to address? While pitavastatin magnesium is effective, it does not uniquely address an unmet need in terms of mechanism of action or broad patient applicability compared to other statins. Its value proposition lies in its efficacy, safety profile, and potential cost-effectiveness, especially in generic formulations and combination therapies.

5. What is the typical lifespan of a pharmaceutical patent for a drug like pitavastatin magnesium, and what is the impact of its expiry on investment? The lifespan of a pharmaceutical patent can vary but typically extends for 20 years from the filing date, with potential for extensions. For pitavastatin magnesium, the original composition of matter patents have expired. Patent expiry allows for generic competition, which drastically reduces the price of the drug and shifts investment focus from branded sales revenue to generic manufacturing efficiency, market share acquisition, and volume-based profitability.

Citations

[1] U.S. Patent 4,994,459. (1991). Method for treating hypercholesterolemia.

[2] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA website] (Specific retrieval date is not applicable as this is an ongoing resource).

[3] European Medicines Agency. (n.d.). Human Medicines. Retrieved from [EMA website] (Specific retrieval date is not applicable as this is an ongoing resource).

[4] Pharmaceuticals and Medical Devices Agency. (n.d.). Drug Approvals. Retrieved from [PMDA website] (Specific retrieval date is not applicable as this is an ongoing resource).

[5] Kowa Pharmaceutical Co., Ltd. (Various Years). Annual Reports and Investor Relations Filings. (Specific reports and dates depend on data access).

[6] GlobalData. (Various Years). Pharmaceutical Market Analysis Reports. (Specific reports depend on subscription and data access).

[7] EvaluatePharma. (Various Years). Drug Intelligence and Market Analysis. (Specific reports depend on subscription and data access).